Efficacy, cardiac safety and tolerability of sertindole: A drug surveillance

International Clinical Psychopharmacology

Volumn 15, Issue 4, 2000, Pages 207-214

  Pezawas, L ^a   Quiner, S ^a   Moertl, D ^a   Tauscher, J ^a   Barnas, C ^a   Kufferle B ^a   Wolf, R ^a   Kasper, S ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Atypical antipsychotics; Neuroleptics; QT interval; Schizophrenia; Sertindole

Indexed keywords

NEUROLEPTIC AGENT; SERTINDOLE;

ADULT; AKATHISIA; ARTICLE; CARDIOVASCULAR SYSTEM; CLINICAL TRIAL; DELUSION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; ELECTROCARDIOGRAM; EXTRAPYRAMIDAL SYMPTOM; FEMALE; FEVER; HALLUCINOSIS; HEART ARRHYTHMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MOTOR DYSFUNCTION; PARKINSONISM; PRIORITY JOURNAL; PSYCHOSIS; QT INTERVAL; SCHIZOPHRENIA; SEXUAL DYSFUNCTION;

EID: 0033933149     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-200015040-00003     Document Type: Article

References (34)

1. Arnt J, Skarsfeldt T (1998) Do novel antipsychotics have similar pharmacological characteristics? Neuropsychopharmacology 18:63-101.
2. Daniel DG, Wozniak P, Mack RJ, McCarty BG (1998) Long-term efficacy and safety comparison of sertindole and haloperidol in the treatment of schizophrenia. The Sertindole Study Group. Psychopharmacol Bull 34:61-69.
3. Dinan TG (1987) Calcium-activated potassium conductance. An alternative to the dopamine hypothesis of neuroleptic action? Br J Psychiatry 151:455-459.
4. Drici MD, Wang WX, Liu XK, Woosley R, Flockhart DA (1998) Prolongation of QT Interval in isolated feline hearts by antipsychotic drugs. J Clin Psychopharmacol 18:477-481.
5. Eder C (1998) Ion channels in microglia (brain macrophages). Am J Physiol 275:C327-C342.
6. Elming H, Holm E, Jun L, Torp-Pedersen C, Kober L, Kircshoff M, et al. (1998) The prognostic value of the QT interval and QT interval dispersion in all-cause and cardiac mortality and morbidity in a population of Danish citizens. Eur Heart J 19:1391-1400.
7. Fritze J, Bandelow B (1998) The QT interval and the atypical antipsychotic, sertindole. Int J Psych Clin Pract 2:265-273.
8. Funck-Bretano C, Jaillon P (1993) Rate-corrected QT interval: techniques and limitations. Am J Cardiol 72:17B-22B.
9. Gargus JJ, Fantino E, Gutman GA (1998) A piece in the puzzle: an ion channel candidate gene for schizophrenia. Mol Med Today 4:518-524.
10. Garson A (1993) How to measure the QT interval-what is normal? Am J Cardiol 72:14B-16B.
11. H Lundbeck A/S (1998) Serdolect safety-update report. February 1998. Copenhagen, Denmark: Lundbeck A/S.
12. Hakkarainen H, Hattab JR, Venulet J (1984) Phase IV research by pharmaceutical companies. Pharmacopsychiatry 17:168-175.
13. Hale A, Van der Drught M, Friberg HH, Wehnert A (1996) Dose ranging study comparing 4 doses of sertindole and 1 dose of haloperidol in schizophrenic patients. Eur Neuropsychopharmacol 6 (Suppl. 3):61.
14. Hansen TE, Casey DE, Hoffman WF (1997) Neuroleptic intolerance. Schizophr Bull 23:567-582.
15. Kane JM (1996) Schizophrenia. New Engl J Med 334:34-41.
16. Kane JM (1998) Sertindole: a review of clinical efficacy. Int Clin Psychopharmacol 13 (Suppl. 3):S63-S64.
17. Kasper S (1998) How much do novel antipsychotics benefit the patient? Int Clin Psychopharmacol 13 (Suppl. 3):S71-S77.
18. Kasper S, Quiner S, Pezawas L (1998a) A review of the benefit: risk profile of sertindole. Int J Psychiatry Clin Pract 2 (Suppl. 2):S59-S64.
19. 123I-IBZM SPECT study. Psychopharmacology 136:367-373.
20. Kasper S, Hale A, Azorin JM, Möller HJ (1999) Benefit-risk evaluation of olanzapine, risperidone, and sertindole in the treatment of schizophrenia. Eur Arch Psychiatr Clin Neurosci 249 (Suppl. 2):II/2-II/14.
21. Macfarlane PW (1998) Measurement of QT dispersion. Heart 80:421-423.
22. Morganroth J, Brozovich FV, McDonald JT, Jacobs RA (1991) Variability of the QT measurement in healthy men, with implications for selection of an abnormal QT value to predict drug toxicity and proarrhythmia. Am J Cardiol 67:774-776.
23. Moertl D, Heiden A, Porenta G, Kasper S (1998) Kardiovaskuläre Nebenwirkungen bei Neuroleptika-Therapie. Pharmakotherapie 5:109-114.
24. Piccirello G, Viola E, Nocco M, Santagada E, Durante M, Bucca C, Marigliano M (1999) Autonomic modulation and QT interval dispersion in hypertensive subjects with anxiety. Hypertension 34:242-246.
25. Rampe D, Murawsky K, Grau J, Lewis E (1998) The antipsychotic agent sertindole is a high affinity antagonist on the human cardiac potassium channel HERG. J Pharmacol Exp Ther 286:788-793.
26. Roden DM (1988) Role of the electrocardiogram in determing electrophysiologic end points of drug therapy. Am J Cardiol 62:34H-38H.
27. Studenik C, Lemmens-Gruber R, Heistracher P (1999) Proarrhythmic effects of antidepressants and neuroleptic drugs on isolated, spontaneously beating guinea-pig Purkinje fibers. Eur J Pharm Sci 7:113-118.
28. Suessbrich H, Schonherr R, Heinemann SH, Attali B, Lang F, Busch AE (1997) The inhibitory effect of the antipsychotic drug haloperidol on HERG potassium channel expressed in Xenopus oocytes. Br J Pharmacol 120:969-974.
29. + channels as pharmacological targets: present and future implications. Biochem Pharmacol 55:1174-1176.
30. 2A receptors by sertindole in the rat brain. J Psychiatry Neurosci 23:157-162.
31. Tamminga CA (1997) Sertindole, a new antipsychotic drug. Today's Therapeut Trends 14:267-281.
32. Tamminga CA, Mack RJ, Grannemann GR, Silber CJ, Kashkin KB (1997) Sertindole in the treatment of psychosis in schizophrenia: efficacy and safety. Int Clin Psychopharmacol 12 (Suppl. 1):S29-S35.
33. Van Kammen DP, McEvoy JP, Targum SD, Kardatzke, Sebree TB, Sertindole Study Group (1996) A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacology 124:168-175.
34. Zimbroff DL, Kane JM, Tamminga CA, Daniel DG, Mack RJ, Wozniak PJ, et al., and Sertindole Study Group (1997) Controlled dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Am J Psychiatry 154:782-791.